Cargando…

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

BACKGROUND: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: El Helali, Aya, Lam, Tai-Chung, Ko, Elaine Yee-Ling, Shih, David J.H., Chan, Chun Kau, Wong, Charlene H.L., Wong, Jason W.H., Cheung, Lydia W.T., Lau, Johnny K.S., Liu, Anthony P.Y., Chan, Ann S.Y., Loong, Herbert H., Lam, Stephen Tak Sum, Chan, Godfrey Chi-Fung, Lee, Victor H.F., Yuen, Kwok Keung, Ng, Wai-Tong, Lee, Anne W.M., Ma, Edmond S.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398587/
https://www.ncbi.nlm.nih.gov/pubmed/37547050
http://dx.doi.org/10.1016/j.lanwpc.2023.100775
_version_ 1785084084814348288
author El Helali, Aya
Lam, Tai-Chung
Ko, Elaine Yee-Ling
Shih, David J.H.
Chan, Chun Kau
Wong, Charlene H.L.
Wong, Jason W.H.
Cheung, Lydia W.T.
Lau, Johnny K.S.
Liu, Anthony P.Y.
Chan, Ann S.Y.
Loong, Herbert H.
Lam, Stephen Tak Sum
Chan, Godfrey Chi-Fung
Lee, Victor H.F.
Yuen, Kwok Keung
Ng, Wai-Tong
Lee, Anne W.M.
Ma, Edmond S.K.
author_facet El Helali, Aya
Lam, Tai-Chung
Ko, Elaine Yee-Ling
Shih, David J.H.
Chan, Chun Kau
Wong, Charlene H.L.
Wong, Jason W.H.
Cheung, Lydia W.T.
Lau, Johnny K.S.
Liu, Anthony P.Y.
Chan, Ann S.Y.
Loong, Herbert H.
Lam, Stephen Tak Sum
Chan, Godfrey Chi-Fung
Lee, Victor H.F.
Yuen, Kwok Keung
Ng, Wai-Tong
Lee, Anne W.M.
Ma, Edmond S.K.
author_sort El Helali, Aya
collection PubMed
description BACKGROUND: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong. METHODS: Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was used in the survival analyses, and hazard ratios were calculated using univariate Cox regression. FINDINGS: 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB recommendations. These patients achieved a significantly longer median OS than those who did not receive MTB-guided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively. INTERPRETATION: Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTB-guided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in real-world clinical practice. FUNDING: The study was supported by the 10.13039/100007422Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.
format Online
Article
Text
id pubmed-10398587
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103985872023-08-04 The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours El Helali, Aya Lam, Tai-Chung Ko, Elaine Yee-Ling Shih, David J.H. Chan, Chun Kau Wong, Charlene H.L. Wong, Jason W.H. Cheung, Lydia W.T. Lau, Johnny K.S. Liu, Anthony P.Y. Chan, Ann S.Y. Loong, Herbert H. Lam, Stephen Tak Sum Chan, Godfrey Chi-Fung Lee, Victor H.F. Yuen, Kwok Keung Ng, Wai-Tong Lee, Anne W.M. Ma, Edmond S.K. Lancet Reg Health West Pac Articles BACKGROUND: The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong. METHODS: Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was used in the survival analyses, and hazard ratios were calculated using univariate Cox regression. FINDINGS: 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB recommendations. These patients achieved a significantly longer median OS than those who did not receive MTB-guided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively. INTERPRETATION: Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTB-guided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in real-world clinical practice. FUNDING: The study was supported by the 10.13039/100007422Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report. Elsevier 2023-04-28 /pmc/articles/PMC10398587/ /pubmed/37547050 http://dx.doi.org/10.1016/j.lanwpc.2023.100775 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
El Helali, Aya
Lam, Tai-Chung
Ko, Elaine Yee-Ling
Shih, David J.H.
Chan, Chun Kau
Wong, Charlene H.L.
Wong, Jason W.H.
Cheung, Lydia W.T.
Lau, Johnny K.S.
Liu, Anthony P.Y.
Chan, Ann S.Y.
Loong, Herbert H.
Lam, Stephen Tak Sum
Chan, Godfrey Chi-Fung
Lee, Victor H.F.
Yuen, Kwok Keung
Ng, Wai-Tong
Lee, Anne W.M.
Ma, Edmond S.K.
The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title_full The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title_fullStr The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title_full_unstemmed The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title_short The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
title_sort impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398587/
https://www.ncbi.nlm.nih.gov/pubmed/37547050
http://dx.doi.org/10.1016/j.lanwpc.2023.100775
work_keys_str_mv AT elhelaliaya theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT lamtaichung theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT koelaineyeeling theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT shihdavidjh theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT chanchunkau theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT wongcharlenehl theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT wongjasonwh theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT cheunglydiawt theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT laujohnnyks theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT liuanthonypy theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT chanannsy theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT loongherberth theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT lamstephentaksum theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT changodfreychifung theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT leevictorhf theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT yuenkwokkeung theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT ngwaitong theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT leeannewm theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT maedmondsk theimpactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT elhelaliaya impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT lamtaichung impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT koelaineyeeling impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT shihdavidjh impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT chanchunkau impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT wongcharlenehl impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT wongjasonwh impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT cheunglydiawt impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT laujohnnyks impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT liuanthonypy impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT chanannsy impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT loongherberth impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT lamstephentaksum impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT changodfreychifung impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT leevictorhf impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT yuenkwokkeung impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT ngwaitong impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT leeannewm impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours
AT maedmondsk impactofthemultidisciplinarymoleculartumourboardandintegrativenextgenerationsequencingonclinicaloutcomesinadvancedsolidtumours